Real‑world and prospective data demonstrate the role of clearance‑informed, precision‑guided dosing in supporting individualized treatment decisions and durable disease control SAN DIEGO, CA / ACCESS ...

Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

Samsung Bioepis Co., Ltd. today released its Second Quarter 2026 Biosimilar Market Report, marking the thirteenth edition of the Quarterly Biosimilar Market Report in the United States (US). The ...

Switching to guselkumab for psoriasis treatment was associated with the greatest rate of treatment persistence when compared with other therapies.

Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include ...

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ ...

Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and ...

Domestic researchers have made significant progress toward developing artificial intelligence (AI)-based antibody drugs that ...

Discover tattoo-associated uveitis, a rare eye inflammation condition linked to delayed immune reactions to tattoo ink, and ...

More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it. Humira, the brand name of AbbVie’s adalimumab, is prescribed to treat inflammatory diseases ...

Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

Objective While sustained remission is the treatment goal for rheumatoid arthritis (RA), its long-term remission remains ...